1
/
of
1
Elabscience
SKU:PKSH031834
Recombinant Human TLR4/CD284 Protein (His Tag)
Recombinant Human TLR4/CD284 Protein (His Tag)
Regular price
$732.00 USD
Regular price
Sale price
$732.00 USD
Unit price
/
per
Shipping calculated at checkout.
Couldn't load pickup availability
Introducing the Recombinant Human TLR4/CD284 Protein (HIS TAG), a cutting-edge product meticulously engineered to meet the demands of advanced scientific research. This protein, derived from human Toll-like receptor 4 (TLR4) and CD284, boasts a high level of purity and quality, making it an indispensable tool for various applications in the field of immunology.
The Recombinant Human TLR4/CD284 Protein (HIS TAG) is produced through a state-of-the-art recombinant DNA technology, ensuring its authenticity and reliability. With the inclusion of a histidine (HIS) tag, this protein offers enhanced versatility and ease of purification, facilitating streamlined experimental procedures.
This protein exhibits exceptional stability and solubility, enabling researchers to conduct comprehensive investigations into the intricate mechanisms of TLR4/CD284 signaling pathways. Its precise amino acid sequence, derived from human sources, guarantees optimal compatibility with human cellular systems, thereby yielding accurate and reliable results.
The Recombinant Human TLR4/CD284 Protein (HIS TAG) is an invaluable asset for studies involving innate immune responses, inflammation, and host-pathogen interactions. Its application extends to the elucidation of TLR4-mediated signaling cascades, paving the way for novel therapeutic interventions targeting immune-related disorders.
We take immense pride in delivering this product with the utmost commitment to quality assurance. Rigorous quality control measures are implemented throughout the manufacturing process, ensuring the consistency and integrity of each batch. The Recombinant Human TLR4/CD284 Protein (HIS TAG) is supplied in a lyophilized form, preserving its stability and extending its shelf life.
In summary, the Recombinant Human TLR4/CD284 Protein (HIS TAG) represents a pinnacle of scientific innovation, offering researchers an indispensable tool to unravel the complexities of TLR4/CD284 biology. With its exceptional purity, stability, and compatibility, this protein is poised to revolutionize the field of immunological research.
The Recombinant Human TLR4/CD284 Protein (HIS TAG) is produced through a state-of-the-art recombinant DNA technology, ensuring its authenticity and reliability. With the inclusion of a histidine (HIS) tag, this protein offers enhanced versatility and ease of purification, facilitating streamlined experimental procedures.
This protein exhibits exceptional stability and solubility, enabling researchers to conduct comprehensive investigations into the intricate mechanisms of TLR4/CD284 signaling pathways. Its precise amino acid sequence, derived from human sources, guarantees optimal compatibility with human cellular systems, thereby yielding accurate and reliable results.
The Recombinant Human TLR4/CD284 Protein (HIS TAG) is an invaluable asset for studies involving innate immune responses, inflammation, and host-pathogen interactions. Its application extends to the elucidation of TLR4-mediated signaling cascades, paving the way for novel therapeutic interventions targeting immune-related disorders.
We take immense pride in delivering this product with the utmost commitment to quality assurance. Rigorous quality control measures are implemented throughout the manufacturing process, ensuring the consistency and integrity of each batch. The Recombinant Human TLR4/CD284 Protein (HIS TAG) is supplied in a lyophilized form, preserving its stability and extending its shelf life.
In summary, the Recombinant Human TLR4/CD284 Protein (HIS TAG) represents a pinnacle of scientific innovation, offering researchers an indispensable tool to unravel the complexities of TLR4/CD284 biology. With its exceptional purity, stability, and compatibility, this protein is poised to revolutionize the field of immunological research.
Share
